Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02643420 · ClinicalTrials.gov registry record · Phase 3
SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)
A Phase 3 study, sponsored by Spectrum Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 406
- Enrollment target
NCT02643420 is a Phase 3 study that has completed, run by Spectrum Pharmaceuticals. The registered enrollment target is 406 participants.
The verdict
NCT02643420, a Phase 3 study, has completed, sponsored by Spectrum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 406 participants
- Enrollment target
Study Summary
The purpose of this study was to compare the efficacy of a single dose of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC), as measured by the duration of severe neutropenia (DSN) in Cycle 1.
Interventions
- DRUG Cyclophosphamide
- DRUG Docetaxel
- DRUG Pegfilgrastim
- DRUG SPI-2012
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 406 participants |
| Start Date | 2016-01-19 |
| Est. Completion | 2018-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02643420
The ClinicalTrials.gov registry entry for NCT02643420 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 406 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT02643420 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02643420 about?
NCT02643420 is a clinical study titled "SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)". The purpose of this study was to compare the efficacy of a single dose of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC), as measured by the duration of severe neutropenia (DSN) in Cycle 1.
What is the current status of trial NCT02643420?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 406 participants. The study started on 2016-01-19. Estimated completion is 2018-10-31.
What interventions are being tested in trial NCT02643420?
The interventions under investigation include: Cyclophosphamide (DRUG), Docetaxel (DRUG), Pegfilgrastim (DRUG), SPI-2012 (DRUG).
Who is sponsoring clinical trial NCT02643420?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.